The present regulatory environment thus favors explicit uncertainty mapping, not the elimination of uncertainty as a precondition for development
Oral Glutamine Increases Circulating GLP-1, Glucagon and Insulin Levels in Lean, Obese and Type 2 Diabetic Subjects. The American Journal of Clinical Nutrition, vol
2,3 Against this backdrop, oral GLP-1 receptor agonists are emerging as an increasingly important area of focus, as companies look to extend growth beyond injectables and broaden access to obesity care
SGLT2is, and GLP-1 RAs in particular promote weight loss, and therefore especially may be of benefit, given that overweight and obesity is increasingly prevalent (62%) in individuals with type 1 diabetes [12]
What works in a rat study may not translate to humans